About | Free Trial

Last Update

2016-02-21T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Franklin Pass?

Dr. Franklin Pass

Chief Executive Officer

Medi-Ject Corporation

Direct Phone: (612) ***-****       

Medi-Ject Corporation

161 Cheshire Lane Suite 100

Minneapolis, Minnesota 55441

United States

Company Description

Medi-Ject Corporation develops, manufactures and markets novel medical devices, called jet injectors, which allow people to self-inject drugs without using a needle. The Company makes a small spring-action device and the attached disposable plastic syring... more

Find other employees at this company (1)

Background Information

Affiliations

Secretary-Treasurer
American Academy of Dermatology

Founder
Molecular Genetics , Inc.

Education



University of Minnesota



University of Minnesota Medical School

M.D.

medical degree

University of Minnesota , School of Medicine

Web References (30 Total References)


A Blood Test For Women With Breast Cancer

www.martelldiagnostic.com [cached]

Franklin Pass, M.D., Chairman and CEO - Frank graduated from the University of Minnesota and University of Minnesota Medical School and then trained at Oregon Health Sciences University as a dermatologist. Following a dermatology residency and military service, he joined the faculty of Albert Einstein College of Medicine. At Einstein, he spent six years in an immunochemistry and molecular virology laboratory. He organized and led the residency training program in dermatology and collaborated in early human papilloma virus research. He returned to the faculty of the University of Minnesota Medical School in 1973 to continue his HPV research, which ultimately resulted in the formation of Molecular Genetics, Inc. in 1979. Dr. Pass formed MOGEN, a Dutch plant biotechnology research company that today is part of Syngenta. Dr. Pass left Molecular Genetics in 1987 to found Bioseeds International, Ltd. Bioseeds was purchased by Calgene in 1990. Dr. Pass then became CEO of Medi-Ject Corporation, assembled a cadre of engineers and greatly advanced the mechanics of needle-free drug delivery. Medi-Ject was merged with a Swiss drug delivery company in 2000 and today is Antares Pharma, Inc. In all, Dr. Pass has been a co-founder and CEO of six companies in the field of agricultural biotechnology, drug delivery, pharmaceutical discovery and diagnostics, three of which became public corporations with eventual shareholder value in excess of $4.0 billion. He has been a co-founder and leader of three professional associations and served as a director of several civic arts organizations. His academic and industry contributions in the field of HPV helped to delineate the role of HPV in human cancer and in the design of papilloma virus vaccines, and he supported the fundamental development of genetically modified corn. Dr. Pass has published over forty scientific papers.

...
Doug worked with Dr. Pass at two early stage biotechnology ventures dating back to 1980.
...
Richard is a molecular biologist, who began his career as a postdoc in a University of Minnesota lab with Dr. Pass.


SEC EDGAR Submission 0001193125-05-061028

www.sec.gov [cached]

Continuing as directors for the Company but not subject to re-election were directors Frank Massino, George Fellows, Kevin McCarthy, Anthony Williams and Dr. Franklin Pass.

...
Franklin Pass
Director
...
Dr. Franklin Pass was appointed a director in February 2002.Since March 2001 he has been Vice Chairman of Antares Pharma, Inc., which develops and markets pharmaceutical delivery systems, and is Managing Director at Cherry Tree Securities, a Minnesota-based investment banking group which provided consulting services to the Company from January 2002 to June 2002.Since 2003 Dr. Pass has also served as a Director of Peptx, Inc., a privately held venture stage drug development company.Previously, Dr. Pass was Chairman and CEO of Antares Pharma, Inc., BioSeeds International, Ltd., and Molecular Genetics, Inc. (MGI Pharma, Inc.), which he co-founded.He served as CEO of Medi-ject Corp. from 1993 to 2001.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine.
...
The Board of Directors has determined that Dr. Franklin Pass, a member of the Audit Committee, qualifies as an "audit committee financial expert," and is "independent," as defined in applicable SEC rules.


Franklin ...

www.sec.gov [cached]

Franklin Pass

Director
...
Franklin Pass was appointed a Director in February 2002 and was re-elected by shareholder at the Annual General Meeting in May 2002.Since March 2001, he has been Vice Chairman of Antares Pharma, Inc. (formerly known as Mediject Corporation), which develops and markets pharmaceutical delivery systems, and is a Managing Director of Cherry Tree Development LLC, a Minnesota-based investment banking group.From 1993 to 2000, Dr. Pass was Chairman and CEO of Mediject Corporation.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine.
...
The Compensation Committee currently consists of Dr. Pass (Chairman) and Messrs.
...
During 2003, the Compensation Committee consisted initially of Dr. Pass (Chairman).
...
Dr. Pass replaced Mr. Williams as Chairman in 2004.
...
The Audit Committee currently consists of Mr. Fellows (Chairman), Dr. Pass and Dr. Thieme.
...
During 2003, the Audit Committee consisted initially of Mr. Tobler (Chairman), Dr. Pass and Dr. Thieme.
...
Williams and McCarthy, Mr. Tobler and Dr. Pass were replaced on the Committee by Messrs.
...
Dr. Pass replaced Mr. McCarthy in October 2004.
...
McCarthy and Pass.
...
Dr. Pass is "independent" within the meaning of the listing standards of the Nasdaq Stock Market.
The Nominating Committee was established in October 2003.The Nominating Committee currently consists of Messrs.Fellows (Chairman) and Williams and Dr. Pass.
...
Mr. McCarthy stepped down in October 2004 in favor of Dr. Pass.
...
The Board has determined that the following directors of the Company (constituting a majority of all directors) are "independent" within the meaning of the listing standards of the Nasdaq Stock Market: Mr. Fellows, Mr. Williams, Dr. Pass and Dr. Thieme.
...
Franklin Pass
...
Includes the following number of shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days of September 30, 2004: Mr. Massino: 3,050,000; Dr. Thieme: 280,000; Mr. Tobler: 845,000; Mr. Slade: 185,000; Dr. Pass: 150,000;Mr.
...
Includes the following number of shares issuable within 60 days from deferred compensation accounts maintained by certain executive officers and directors of the Company pursuant to deferred compensation arrangements entered into by such executive officers and directors with the Company effective January 1, 2004 pursuant to which ten percent of base salary (in the case of the executive officers) or quarterly director fees (in the case of non-employee directors) could be deferred and applied to Ordinary share equivalent units: Mr. Massino: 44,466; Mr. Tobler 8,501; Dr. Pass 15,766; Mr. Nichols 33,872; Mr. McCarthy 15,766; Mr. Fellows 15,766; Mr. Williams 15,766; and Mr. Holsworth: 25,787.
...
Cherry Tree Development, LLC, an entity affiliated with board member Dr. Franklin Pass, was compensated a total of $36,000 for its services during 2003.


Franklin ...

www.sec.gov [cached]

Franklin Pass

Director
...
Franklin Pass was appointed a Director in February 2002 and was re-elected by shareholder at the Annual General Meeting in May 2002.Since March 2001, he has been Vice Chairman of Antares Pharma, Inc. (formerly known as Mediject Corporation), which develops and markets pharmaceutical delivery systems, and is a Managing Director of Cherry Tree Development LLC, a Minnesota-based investment banking group.From 1993 to 2000, Dr. Pass was Chairman and CEO of Mediject Corporation.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine.
...
The Compensation Committee currently consists of Dr. Pass (Chairman) and Messrs.
...
During 2003, the Compensation Committee consisted initially of Dr. Pass (Chairman).
...
Dr. Pass replaced Mr. Williams as Chairman in 2004.
...
The Audit Committee currently consists of Mr. Fellows (Chairman), Dr. Pass and Dr. Thieme.
...
During 2003, the Audit Committee consisted initially of Mr. Tobler (Chairman), Dr. Pass and Dr. Thieme.
...
Williams and McCarthy, Mr. Tobler and Dr. Pass were replaced on the Committee by Messrs.
...
Dr. Pass replaced Mr. McCarthy in October 2004.
...
McCarthy and Pass.
...
Dr. Pass is "independent" within the meaning of the listing standards of the Nasdaq Stock Market.
The Nominating Committee was established in October 2003.The Nominating Committee currently consists of Messrs.Fellows (Chairman) and Williams and Dr. Pass.
...
Mr. McCarthy stepped down in October 2004 in favor of Dr. Pass.
...
The Board has determined that the following directors of the Company (constituting a majority of all directors) are "independent" within the meaning of the listing standards of the Nasdaq Stock Market: Mr. Fellows, Mr. Williams, Dr. Pass and Dr. Thieme.
...
Franklin Pass
...
Includes the following number of shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days of September 30, 2004: Mr. Massino: 3,050,000; Dr. Thieme: 280,000; Mr. Tobler: 845,000; Mr. Slade: 185,000; Dr. Pass: 150,000;Mr.
...
Includes the following number of shares issuable within 60 days from deferred compensation accounts maintained by certain executive officers and directors of the Company pursuant to deferred compensation arrangements entered into by such executive officers and directors with the Company effective January 1, 2004 pursuant to which ten percent of base salary (in the case of the executive officers) or quarterly director fees (in the case of non-employee directors) could be deferred and applied to Ordinary share equivalent units: Mr. Massino: 44,466; Mr. Tobler 8,501; Dr. Pass 15,766; Mr. Nichols 33,872; Mr. McCarthy 15,766; Mr. Fellows 15,766; Mr. Williams 15,766; and Mr. Holsworth: 25,787.
...
Cherry Tree Development, LLC, an entity affiliated with board member Dr. Franklin Pass, was compensated a total of $36,000 for its services during 2003.


Of the current Directors, two are ...

www.sec.gov [cached]

Of the current Directors, two are Managing or Executive Directors, and three were appointed by the Board of Directors since the last Annual Meeting, leaving only two Directors subject to this rule, namely Franklin Pass and Uwe Thieme.

...
Franklin Pass
Director
...
Dr. Franklin Pass was appointed a Director in February 2002.Since March 2001, he has been Vice Chairman of Antares Pharma, Inc. (formerly known as Mediject Corporation), which develops and markets pharmaceutical delivery systems, and is a Managing Director of Cherry Tree Development LLC, a Minnesota-based investment banking group.From 1993 to 2000, Dr. Pass was Chairman and CEO of Mediject Corporation.He has served as Director of the American Academy of Dermatology, Director of Dermatology at the Albert Einstein College of Medicine, and Clinical Professor at the University of Minnesota, Department of Dermatology.He received his medical degree from the University of Minnesota, School of Medicine.
...
Tobler and Georgiev were replaced on the Committee by Dr. Pass and Mr. Nichols, a former Director.
...
Upon Mr. Fellows' election to the Board, Dr. Pass was replaced on the Committee by Mr. Fellows.
...
Williams and McCarthy, Mr. Tobler and Dr. Pass were replaced on the Committee by Messrs.
...
The special task force was in existence from February through May 2002 and consisted of Dr. Pass, Mr. Tobler and Wade Nichols, a former Director.
...
Dr. Pass and Messrs.
...
The aggregate amounts received by the various Directors or their affiliated companies for consulting services during 2002, including consulting services provided as a member of the special task force, were: Mr. Pass, $30,000; Mr. Tobler, $139,000; Mr. Nichols, $105,000.
...
Total option grants were: Mr. Tobler, 225,000 shares, Mr. Nichols (a former Director), 150,000 shares, Mr. Georgiev (a former Director), 225,000 shares, and Dr. Pass, 150,000 shares.
...
Franklin Pass
...
Includes the following number of shares issuable upon exercise of options that are currently exercisable or will become exercisable within 60 days of September 15, 2003: Mr. Massino: 2,575,000; Dr. Thieme: 280,000; Mr. Tobler: 845,000; Mr. Slade: 172,500; Dr. Pass: 150,000; Mr. Nichols: 150,000.
...
From June 16, 2003 to September 16, 2003, the Company engaged Cherry Tree Development, LLC ("CTD"), an affiliate of Cherry Tree Securities, of which Dr. Pass is a Managing Director, as the Company's financial advisor in connection with the possible sale or licensing of the Company's patented Invicorp® erectile dysfunction product and Reliaject® autoinjector.During that period, CTD was paid a retainer of $12,000 per month plus expenses and, if a covered transaction occurs within a specified period, would be entitled to a fee equal to 8% of each of (i) all consideration received by the Company at the time of sale or licensing, (ii) milestone payments and (iii) developmental payments, less monthly fees paid.In addition, CTD was paid the $30,000 in consulting fees due to Dr. Pass for his special task force services from April 2002 to June 2002 described under "Board Meetings, Committees and Compensation" above.

Similar Profiles

Other People with this Name

Other people with the name Pass

Florence Pass
Museums & Must-sees

Paula Pass
Zonta Club

Ian Pass
Sanford-Burnham Medical Research Institute

Bryan Pass
Longdown Activity Farm

Shannon Pass
Christianbook.com

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory